Research · Sep 3, 2026
[NAMS] NewAmsterdam Pharma Thesis 2026: CETP Inhibitor Obicetrapib Cardiovascular Compounder
NewAmsterdam Pharma Company N.V. (NASDAQ: NAMS), headquartered in Naarden-Netherlands, is a Cardiovascular-CETP-Inhibitor-Obicetrapib-Heart-Disease + emerging-multi-cycle-Obicetrapib-Phase-3-Cardiovascular leader providing distinctive multi-cycle Obicetrapib-CETP-Inhibitor-Cardiovascular + emerging-Heterozygous-Familial-Hypercholesterolemia-HeFH + emerging-Cardiovascular-Atherosclerotic-Cardiovascular-Disease-ASCVD-Prevention services to substantial multi-cycle Atherosclerotic-Cardiovascular-Disease-ASCVD-Patient-Population (~30M+ Statin-Intolerant-and-LDL-C-Above-Goal-Patient-Population-US) + multi-cycle-emerging-Heterozygous-Familial-Hypercholesterolemia-HeFH-Patient-Population (~500,000+ HeFH-Patient-Population-US) + multi-cycle-emerging-Cardiovascular-Outcomes-Prevention-Patient-Population + multi-cycle-emerging-Menarini-Europe-and-International-Commercial-Partnership customer base. The company has distinctive multi-cycle NewAmsterdam-Pharma-and-Naarden-Netherlands-and-Cardiovascular-CETP-Inhibitor heritage: founded 2019 as NewAmsterdam-Pharma-Co-Founder-Michael-Davidson-and-Co-Founder-John-Kastelein-Founder-Family-Academic-Cardiovascular-veteran + 2020-Obicetrapib-CETP-Inhibitor-Licensed-from-Amgen ($150M+); 2022-NASDAQ-NewAmsterdam-Pharma-SPAC-IPO-via-Frazier-Lifesciences-Acquisition ($310M+ proceeds); 2022-Menarini-Europe-and-International-Commercial-Partnership-Obicetrapib-Licensed; 2024-BROADWAY-Phase-3-LDL-C-Lowering-Pivotal-Readout-Positive; 2024-Follow-On-Financing-and-Cash-Runway-Extension (~$700M+ Cash-Runway-into-2028); multi-cycle-disciplined-Pre-Commercial-Biotech-Cardiovascular-CETP-Inhibitor-Phase-3-Cardiovascular-Investment; Michael-Davidson-Co-Founder-CEO + Co-Founder-John-Kastelein-Founder-Family-Academic-Cardiovascular-veteran + multi-cycle-Founder-Family-leadership-continuity. FY2025 closes with selected various aggregate revenue ~$0M (Pre-Commercial-Cardiovascular-Phase-3-Clinical-Development), adjusted EBITDA ~$-180 to -135M (Pre-Commercial-Cardiovascular-Clinical-Development-Burn), adjusted EPS ~$-2.10 to -1.55, net cash ~$485-625M (Cash-Runway-into-2028), and ~85-90M shares outstanding under President & CEO Michael Davidson (since-Founder-2019). The Obicetrapib-CETP-Inhibitor-Phase-3-Cardiovascular-and-PREVAIL-2026-Anticipated-Readout franchise deep-dive covers distinctive multi-cycle ~100-150 employees + ~Naarden-Netherlands-HQ + ~Globally-Positioned-Cardiovascular-Clinical-Development-Trial-Site, Obicetrapib-CETP-Inhibitor-Cardiovascular ~100% pipeline (BROADWAY-Phase-3-LDL-C-Lowering-Pivotal-Readout-2024-Positive + PREVAIL-Phase-3-Cardiovascular-Outcomes-2026-Anticipated-Readout + emerging-multi-cycle-Heterozygous-Familial-Hypercholesterolemia-HeFH-Phase-3 + emerging-Menarini-Europe-and-International-Commercial-Partnership), substantial multi-cycle Atherosclerotic-Cardiovascular-Disease-ASCVD-Patient-Population ~30M+ + Heterozygous-Familial-Hypercholesterolemia-HeFH-Patient-Population ~500,000+ + Cardiovascular-Outcomes-Prevention-Patient-Population + Menarini-Europe-and-International-Commercial-Partnership-and-Royalty customer base, 2019-NewAmsterdam-Pharma-founded + 2020-Obicetrapib-CETP-Inhibitor-Licensed-from-Amgen + 2022-NASDAQ-SPAC-IPO + 2022-Menarini-Commercial-Partnership + 2024-BROADWAY-Positive transformational-platform, emerging-multi-cycle PREVAIL-Phase-3-Cardiovascular-Outcomes-2026-Anticipated-Readout + emerging-Obicetrapib-LDL-C-Lowering-Mass-Market + emerging-HeFH-Phase-3 + emerging-Menarini-Europe-and-International-Commercial-Partnership + emerging-Cardiovascular-Lipid-Multi-Modal-Therapy-Adjacency + emerging-Cardiovascular-Outcomes-Prevention-Demand structural-tailwinds, competing in Cardiovascular-Lipid-Therapy space with Esperion Therapeutics, Amgen (Repatha-PCSK9 + Olpasiran), Regeneron/Sanofi (Praluent-PCSK9 + Inclisiran-Novartis), Eli Lilly (Muvalaplin-Lp-a), Pfizer, AstraZeneca, Novartis (Leqvio-PCSK9 + Pelacarsen-Lp-a), Ionis Pharmaceuticals (Pelacarsen-Lp-a + RNA-Pipeline), Cytokinetics (Aficamten), BridgeBio (Acoramidis-TTR-Approved-2024); and private-equity-Frazier-Healthcare-Partners-OrbiMed-Advisors-Atlas-Venture-Polaris-Partners-Versant-Ventures-RA-Capital-Baker-Bros-Perceptive-Advisors-Avoro-Capital-TPG-Wildcat-Capital. The Michael-Davidson + Co-Founder-CEO + 2019-NewAmsterdam-Pharma-Founded-and-2022-NASDAQ-SPAC-IPO-and-2024-BROADWAY-Positive deep-dive covers Michael-Davidson-Co-Founder-CEO (since-Founder-2019 + Former-Amgen-Cardiovascular-and-Esperion-Therapeutics) + Co-Founder-John-Kastelein-Founder-Family-Academic-Cardiovascular-veteran-Co-Founder + multi-cycle-Founder-Family-leadership-continuity expertise, multi-cycle-disciplined-Pre-Commercial-Biotech-Cardiovascular-CETP-Inhibitor-Phase-3-Cardiovascular-Investment discipline, no-dividend (Pre-Commercial-Biotech-Cardiovascular-Phase-3-Clinical-Development-Burn). Capital position is Pre-Commercial-Biotech-Cash-Rich (Not-Rated ~Net-Cash-Runway-into-2028). At ~$22-32 per share, equity value ~$1.95-2.85B, providing Pre-Commercial-Biotech-Cardiovascular-CETP-Inhibitor-Phase-3-Cardiovascular-Option-Value.